P-72 A patient preference study on risk thresholds to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma

Abstract

There are various available second-line (2L) systemic treatments for unresectable hepatocellular carcinoma (HCC) utilizing different route of administration (eg, tablets and intravenous [IV] infusions) and having different safety profiles. Therefore, patient preferences should be considered in treatment decisions. However, there are insufficient data regarding patient preferences in the real-world setting in the US. The objectives of this study were to determine patients’ preferences for mode of administration and risk of adverse events (AEs) for regorafenib (4 tablets once daily [QD]) and ramucirumab (once in 2 weeks [Q2W] IV for 30/60 minutes) with similar efficacy profile but different AE profiles, and to determine the proportion of patients who preferred ramucirumab over regorafenib.